Venture capital firms and research institutions have launched the European Life Science Coalition in a bid to strengthen Europe’s VC ecosystem by mobilizing more private and public investment.

The use of DNA scaffolds could mark a turning point in HIV vaccine design. Scientists at Scripps Research and the Massachusetts Institute of Technology (MIT) have created a new vaccine platform based ...

Friedreich’s ataxia (FA), the most common form of hereditary ataxia, is an autosomal recessive neurodegenerative disorder affecting multiple organ systems, and causing cardiomyopathy, scoliosis, ...

Triple-negative breast cancer (TNBC) cells depend on the transcriptional kinases CDK12 and CDK13 to maintain DNA damage response gene expression and manage replication stress. Due to their functional ...

After a prolonged downturn, the med-tech IPO market rebounded in 2025, with deal value surging to $13.01 billion across 31 offerings. The recovery followed two muted years, with just $619 million ...

Med-tech companies looking for capital will have to work harder this year to attract investor attention. Even though investment firms have money to deploy, the capital will go toward more targeted ...

Shenzhen Salubris Pharmaceuticals Co. Ltd. has synthesized interleukin-17A (IL-17A) inhibitors reported to be useful for the treatment of arthritis and psoriasis.

Voronoi Inc. has divulged hepatocyte growth factor receptor (HGFR; c-MET) inhibitors. They are reported to be useful for the treatment of cancer.

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some signaling pathways are well defined in HS, ...

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Biocodex, Calbiotech, Formycon, Helsinn, Liquid, Lotus, Magnapharm, Owlet, Theranexus.

Scientists from Merck Sharp & Dohme LLC and Otsuka Pharmaceutical Co. Ltd. have identified cellular tumor antigen p53 (TP53) Y220C mutant stabilizers reported to be useful for the treatment of cancer.

Yuhan Corp. has disclosed triggering receptor expressed on myeloid cells 2 (TREM2) agonists described as potentially useful for the treatment of neurological disorders.